dup 697 has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies
DuP 697: structure given in first source
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Peng, HL | 1 |
| Zhang, GS | 1 |
| Liu, JH | 1 |
| Gong, FJ | 1 |
| Li, RJ | 1 |
1 other study available for dup 697 and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Dup-697, a specific COX-2 inhibitor, suppresses growth and induces apoptosis on K562 leukemia cells by cell-cycle arrest and caspase-8 activation.
Topics: Apoptosis; Bone Marrow Cells; Caspase 8; Cell Cycle; Cyclooxygenase 2 Inhibitors; Dose-Response Rela | 2008 |